Table 1.
Univariate and multivariate regression analysis of RNASE4 and PSA predictive of biopsy outcome.
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| Outcome variable | Predictor variable | OR (95% CI) | P-value | OR (95% CI) | P-value |
| Biopsy status: Prostate cancer (n = 120) vs. healthy (n = 120) | PSA | 15.97 (6.44–39.60) | <0.0001 | 9.34 (3.90–22.38) | <0.0001 |
| RNASE4 | 1.10 (1.08–1.13) | <0.0001 | 1.07 (1.03–1.12) | <0.0001 | |
| Surgical T-stage: pT3 (n = 19) vs. pT2 (n = 75) | PSA | 1.10 (0.95–1.29) | 0.19 | 1.08 (0.92–1.27) | 0.32 |
| RNASE4 | 1.03 (1.01–1.05) | 0.001 | 1.03 (1.01–1.05) | 0.0007 | |
| Clinical stage: T2 (RNASE4, n = 25; PSA, n = 26) vs. T1 (n = 84) | PSA | 1.00 (0.86–1.17) | 0.97 | 0.95 (0.80–1.13) | 0.50 |
| RNASE4 | 1.04 (1.02–1.06) | 0.0002 | 1.04 (1.02–1.06) | <0.0001 | |
| Biopsy grade: 7 (n = 26) vs. 6 (RNASE4, n = 89; PSA n = 87) | PSA | 1.06 (0.90–1.24) | 0.47 | 1.01 (0.85–1.20) | 0.92 |
| RNASE4 | 1.03 (1.00–1.04) | 0.01 | 1.02 (1.00–1.04) | 0.01 | |
| Surgical gleason 7 (n = 32) vs. 6 (RNASE4, n = 84; PSA n = 66) | PSA | 1.04 (0.86–1.27) | 0.64 | 1.02 (0.84–1.26) | 0.73 |
| RNASE4 | 1.02 (0.99–1.04) | 0.05 | 1.02 (0.99–1.04) | 0.07 | |
OR odds ratio, CI confidence interval. Equal n reported for PSA and RNASE4 if not stratified.